Education
About Us
Working with TipRanks
Follow Us
DBV Technologies (GB:0QAJ)
LSE:0QAJ
Dbv712 250 Mcg
Peanut Allergy, Allergy
Phase III
Recruiting
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
May 27, 2025
―
Dbv712
Allergy, Peanut
Phase III
Active Not Recruiting
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
Feb 14, 2023
―
Dbv712 250 Mcg
Peanut Allergy
Phase III
Completed
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Feb 19, 2019
―
Part A Viaskin Peanut 250 Mcg, Part A Viaskin Peanut 100 Mcg, Part B Viaskin Peanut 250 Mcg
Peanut Allergy
Phase III
Completed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
Jul 05, 2017
―
Viaskin Peanut 250Mcg
Peanut Allergy
Phase III
Completed
Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy
Nov 19, 2015
―
Viaskin Milk 150 Mcg, Viaskin Milk 300 Mcg, Viaskin Milk 500 Mcg
Food Allergy
Phase I/II
Completed
Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy
Aug 20, 2014
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does DBV Technologies (0QAJ) have in its pipeline
0QAJ is currently developing the following drugs: Dbv712 250 Mcg, Dbv712, Dbv712 250 Mcg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.